Recently, we wrote a piece on the need for portfolio management teams to plan well ahead of patent expiry to maximize the number of tactics available to them to extend the lifecycle of the products in their portfolio. Many strategies Continue reading
The earlier pharmaceutical companies begin mapping out their portfolio management options, the more strategies will be available to them and the more success they will have in general. In fact, a senior director at a top 50 pharma company that I recently spoke with told me Continue reading
Key Finding #4 from our Counter-Generics and Biosimilar Threats research:
Short-term strategies are still the most popular, but line-extension tactics gaining favor.
Over the past three years, short-term strategies, including litigation and defensive pricing, have led the way in popularity. Responding companies used each tactic 60% and 57%, respectively. Neither tactic requires very long to move from planning to completion. A large majority Continue reading